EUVIMEDEUVIMED entdecken
Crossref

Yohimbine ameliorates liver inflammation and fibrosis by regulating oxidative stress and Wnt/β-catenin pathway

Nidhi Sharma, Ramakrishna Sistla, Sai Balaji Andugulapati

Phytomedicine · 2024

DOI: 10.1016/j.phymed.2023.155182 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine, 2024. Verfasst von Nidhi Sharma und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Biology, CSIR-Indian Institute of Chemical Technology, Hyderabad-500 007, Telangana, India; Academy of Scientific and Innovativ…. Hauptthemen laut MEDLINE: beta Catenin, Lipopolysaccharides. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 63 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND PURPOSE: Chronic liver injury, caused by various aetiologies, causes recurrent tissue damage, culminating in decreased liver regenerative ability and resulting in fibrosis followed by cirrhosis. In this study, the anti-fibrotic activity of Yohimbine hydrochloride (YHC) was investigated using various in vitro models and in vivo models. METHODS: To assess the anti-inflammatory, antioxidant, and anti-fibrotic effects of YHC, lipopolysaccharide or TGF-β induced differentiation or lipid-induced oxidative-stress models were employed using HLECs, HSC-LX2, and HepG2 cells. Further, thioacetamide (TAA) induced hepatic inflammation/fibrosis models were utilized to validate the YHC's anti-fibrotic activity in rats. RESULTS: Inflammation/differentiation experiments in HLECs and HSC-LX2 revealed that YHC treatment significantly (p < 0.001) mitigated the lipopolysaccharide or TGF-β induced upregulation of inflammatory and fibrotic markers expression respectively. In addition, YHC dose-dependently reduced the TGF-β induced migration and palmitic acid-induced oxidative stress in HepG2 cells. Further, TAA administration (5 weeks) in vivo rat model showed increased inflammatory marker levels/expression, oxidative stress, and pathological abnormalities. Additionally, TAA administration (9 weeks) elevated the fibrotic marker expression, collagen deposition in liver tissues, and shortened longevity in rats. Treatment with YHC dose-dependently mitigated the TAA-induced abnormalities in both inflammation and fibrosis models and improved the survival of the rats. Further mechanistic approaches revealed that TAA administration elevated the JNK, Wnt components and β-catenin expression in hepatic stellate cells and animal tissues. Further treatment with YHC significantly modulated the JNK/Wnt/β-catenin signaling. Moreover, the β-catenin nuclear translocation results showed that β-catenin levels were significantly elevated in the nuclear fraction of TAA control samples and reduced in YHC-treated samples. CONCLUSION: Yohimbine treatment significantly improved inflammation and fibrosis by inhibiting differentiation, oxidative stress, and collagen deposition by partly modulating the JNK/Wnt/β-catenin pathway. These results might serve as a foundation for proposing yohimbine as a potential lead compound for liver fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta CateninLipopolysaccharidesRatsAnimalsYohimbineLiver CirrhosisLiverOxidative StressCollagenHepatic Stellate CellsInflammationTransforming Growth Factor betaThioacetamide

Stichwörter der Autor:innen

And oxidative stressDifferentiationLipid dropletsLobular inflammationMCP-1Septal-fibrosis

Substanzen

beta CateninYohimbineLipopolysaccharidesCollagenTransforming Growth Factor betaThioacetamide

Autor:innen und Institutionen

  • Department of Applied Biology, CSIR-Indian Institute of Chemical Technology, Hyderabad-500 007, Telangana, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh-201 002, India.
  • Department of Applied Biology, CSIR-Indian Institute of Chemical Technology, Hyderabad-500 007, Telangana, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh-201 002, India. Electroni…

Zitieren

APA

Sharma, N., Sistla, R., & Andugulapati, S. B. (2024). Yohimbine ameliorates liver inflammation and fibrosis by regulating oxidative stress and Wnt/β-catenin pathway. Phytomedicine. https://doi.org/10.1016/j.phymed.2023.155182

Vancouver

Sharma N, Sistla R, Andugulapati SB. Yohimbine ameliorates liver inflammation and fibrosis by regulating oxidative stress and Wnt/β-catenin pathway. Phytomedicine. 2024. doi:10.1016/j.phymed.2023.155182

BibTeX
@article{Sharma2024,
  author = {Sharma, Nidhi and Sistla, Ramakrishna and Andugulapati, Sai Balaji},
  title = {Yohimbine ameliorates liver inflammation and fibrosis by regulating oxidative stress and Wnt/β-catenin pathway},
  journal = {Phytomedicine},
  year = {2024},
  doi = {10.1016/j.phymed.2023.155182}
}
Kostenlos starten →